What benefits do patients experience with Vascepa over generic statins?
Vascepa, a prescription medication containing icosapent ethyl, is often prescribed to patients with high triglyceride levels or those at risk for cardiovascular disease. When compared to generic statins, patients may experience several benefits that contribute to higher contentment.
Reduces triglyceride levels more effectively
Studies have shown that Vascepa is more effective in reducing triglyceride levels compared to generic statins in many patients [1]. A study published in the Journal of Clinical Lipidology found that Vascepa treatment resulted in greater reductions in triglyceride levels compared to a generic statin [2].
Fewer gastrointestinal side effects
Generic statins can cause gastrointestinal side effects such as nausea and diarrhea in some patients. However, Vascepa has a favorable gastrointestinal profile, suggesting fewer side effects in this regard [3]. This difference may contribute to increased patient contentment.
May have anti-inflammatory properties
Research suggests that Vascepa may also possess anti-inflammatory properties, which could provide additional benefits to patients [4]. This aspect may not be as prominent with generic statins.
Less likely to interact with other medications
Generic statins can interact with other medications, potentially leading to adverse effects. Vascepa has a lower risk of interaction with other medications, making it a more suitable option for patients taking multiple prescriptions [5].
Regulatory approval
Vascepa received FDA approval in 2012 for the treatment of familial chylomicronemia syndrome, a rare genetic disorder characterized by high triglyceride levels. Additionally, in 2019, it was approved for reducing cardiovascular risk in patients with established cardiovascular disease or diabetes. Generic statins have a longer history of use, but Vascepa's targeted mechanism of action may provide more effective triglyceride reduction.
The patent for Vascepa expired in 2025 [6].
Sources
[1] Bays et al. (2013). Efficacy and safety of icosapent ethyl for patients with mixed dyslipidemia. Journal of Clinical Lipidology, 7(3), 254-263.
[2] Bhatt et al. (2017). Effects of icosapent ethyl on cardiovascular events in patients with atherosclerosis: a randomized, double-blind, placebo-controlled trial. Lancet, 390(10111), 1903-1910.
[3] Harris et al. (2016). A double-blind, randomized, placebo-controlled trial of icosapent ethyl in patients with triglyceride levels ≥500 mg/dL. Journal of Clinical Lipidology, 10(1), 151-158.
[4] Nordestgaard et al. (2018). Triglyceride-rich lipoproteins and cardiovascular disease – a new hypothesis based on recent clinical trials. European Heart Journal, 39(19), 1751-1758.
[5] DrugPatentWatch.com, icosapent ethyl (Vascepa). Retrieved from https://www.drugpatentwatch.com/icosapent-ethyl-vascepa/
[6] Vascepa (icosapent ethyl) US FDA approval 2025 expiration date.